Key facts
- This page summarizes Lars G. Ekman's Form 4 filing for Ultragenyx Pharmaceutical Inc. (RARE).
- 2 reported transactions and 1 derivative row are listed below.
- Accepted by SEC: 28 Jun 2022, 13:53.
Lars G. Ekman - 24 Jun 2022 Form 4 Insider Report for Ultragenyx Pharmaceutical Inc. (RARE)
- Reporting relationship
- Director
- Issuer ticker
- RARE
- Reported as of
- 24 Jun 2022
- Net transaction value
- $0
- SEC form
- 4
- Accepted by SEC
- 28 Jun 2022, 13:53:43 UTC
- Prior SEC filing
- 27 May 2022
- Next SEC filing
- 29 Jun 2022
- Source filing
- View source filing
- Reporting owner signature
- /s/ Karah Parschauer, attorney-in-fact
Source evidence
Original filing metadata and source links for verification.
5 source fields
Reporting owner
1 detail
Key filing fact
Lars G. Ekman filed Form 4 for Ultragenyx Pharmaceutical Inc. (RARE) on 28 Jun 2022.
Change
- Previous filing in this sequence was filed on 27 May 2022.
- Current net transaction value: $0.
Research use
- This tells you what this filing adds before you inspect full transaction and derivative tables.
- You can trace every row back to the original SEC filing document.
Evidence
Filed on Form 4
View source filing
Ownership activity is grounded in SEC Form 4 disclosures.
Reported non-derivative transactions
Shares, units, or other non-derivative securities reported in this filing.
RARE
transaction
Common Stock
Award
- Transaction value
- $0
- Shares
- +3,300
- Change %
- +23%
- Price
- $0.000000
- Shares after
- 17,745
- Date
- 24 Jun 2022
- Ownership
- Direct
- Footnotes
- F1
Reported derivative securities
Options, warrants, convertible securities, or similar derivative positions disclosed in the filing.
RARE
transaction
Derivative
Stock Option (Right to Buy)
Award
- Transaction value
- $0
- Shares
- +6,245
- Change %
- Price
- $0.000000
- Shares after
- 6,245
- Date
- 24 Jun 2022
- Ownership
- Direct
- Underlying class
- Common Stock
- Underlying amount
- 6,245
- Exercise price
- $60.57
- Footnotes
- F2
* marks a reported price that did not pass the local price check.
Additional SEC filing notes
Filing notes and footnotes
Explanation of responses 2 footnotes
Footnote F1
Award of Restricted Stock Units ("RSUs") under the Company's 2014 Incentive Plan. The RSUs shall vest in full on the earlier of (i) the Company's next Annual Meeting of Stockholders or (ii) June 24, 2023.
Footnote F2
The option shall vest in full on the earlier of (i) the Company's next Annual Meeting of Stockholders or (ii) June 24, 2023.